Aries/Aries 2 2018 Research Highlights

December 21, 2018

Aries/Aries 2 2018 Research Highlights

2018 has been a busy and productive year for Dornier MedTech GmbH. As a global market leader in urological disease treatment, we continue to innovate and advance medical technology in the treatment landscape of urology and are committed to establishing a growing body of clinical evidence to build on our clinical leadership. We explore exciting new ways to deliver safe and effective treatment to patients by supporting clinical research with renowned institutions and leading medical professionals. This year, our clinical efforts resulted in 1 journal publication, 5 poster presentations, and 3 newly initiated clinical studies. These efforts include –

Optimizing Dornier Aries/Aries 2 ESWT protocol for Vasculogenic Erectile Dysfunction (ED)

ESWT safe for ED A study by Professor Hatzichristou’s team at the Aristotle University of Thessaloniki was published in the Journal of Sexual Medicine and presented at the 2018 annual congresses of ESSM & EAU. The study showed a treatment of 6 sessions of ESWT was demonstrated to be safe and effective for ED, and further improvements may be obtained with more sessions.

Click here for abstract

ESWT poster Another study by Professor Hatzichristou was awarded Best Poster at the South Eastern European Meeting (SEEM) in September 2018. It showed for the first time that ESWT may be safely applied up to three times per week, without any adverse events. There was a trend towards better results when a higher energy intensity (level 7) was used.

Click here for abstract

Further dissecting the safety, efficacy and mechanism of action of ESWT using Dornier Aries/Aries 2 for ED subpopulations

In the above two studies, Professor Hatzichristou’s team performed a subpopulation analysis of 35 patients who were on a mix of different anti-coagulant / anti-platelet therapy. More studies are required to confirm these results, which suggest that ESWT is safe for ED patients on anticoagulant medication. These results were presented at SEEM 2018.

Read more

A new Dornier Aries 2 clinical study has commenced in collaboration with Dr. Francisco Vigués and Dr. Josep Torremadé at the University Hospital Bellvitge, Spain. This study will investigate the safety and efficacy of ESWT for the treatment of ED caused by nerve-sparing robotic radical prostatectomy (RP).

Read more

A new Dornier Aries 2 clinical study has commenced in collaboration with Dr. Francisco Vigués and Dr. Josep Torremadé at the University Hospital Bellvitge, Spain. This study will investigate the safety and efficacy of ESWT for the treatment of ED caused by nerve-sparing robotic radical prostatectomy (RP).

Investigating safety and efficacy of ESWT using Dornier Aries/Aries 2 for treatment of chronic pelvic pain syndrome (CPPS)*:

MTrPs CPPS ARIES 2
A Dornier Aries clinical study was initiated with Dr. Joe King Chien Lee at the National University Hospital, Singapore, for patients with myofascial trigger points (MTrPs) associated chronic pelvic pain syndrome (CPPS). As the Dornier Aries and Dornier Aries 2 are approved for the treatment of MTrPs, in the shoulder and other muscles, the Dornier Aries and Dornier Aries 2 can also be used effectively for pelvic MTrPs for CPPS patients. A randomized, triple-blind, sham-controlled clinical study was initiated in collaboration with Professor Hatzichristou’s team, to evaluate the safety and efficacy of the Dornier Aries 2 for CPPS. The safety of the treatment will be rigorously investigated using prostate imaging.
*Dornier Aries/Aries 2 is currently not indicated for use in the treatment of CPPS / Chronic Abacterial Prostatitis, and any use of Dornier Aries/Aries 2 in studies relating to this indictaion is for investigational purposes only.

Dornier Medtech is committed to remain a leader in the field of urological treatment and will continue to innovate and deliver high levels of safety and efficacy for our physicians and patients.

  • No events